Retatrutide has emerged as a new treatment in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By boosting these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately results in significant weight loss. While furthe